27.05.2013 - A survey of European clinical geneticists show that a vast majority reject direct-to-consumer (DTC) genetic testing without prior face-to-face counselling.
According to the survey, carried out by Heidi Carmen Howard from French INSERM and Pascal Borry from KU Leuven among 131 EU geneticists, DCT testing for monogenetic and complex diseases is more widespread than thought before. 44% of patients who asked their doctor for genetic counselling, had previously already undertaken a DCT test (Genome Medicine). However, the respondents seem concerned about the DCT test offers. 84% of them disagreed with replacing face-to-face supervision by a medical doctor with supervision via telephone, which is offered by some DTC testing firms. Over 85% of respondents said that they would offer genetic counselling to patients who asked for a consultation after having undergone DTC genetic testing
A majority of clinical geneticists also found it unacceptable to provide non-face-to-face medical supervision for: a pre-symptomatic test for a condition with very high penetrance; a predictive test for a condition that has a “medium” penetrance of 50 to 60%; and for carrier testing. For conditions that are neither treatable nor preventable and for disorders with serious health consequences, clinical geneticists were almost unanimous in expressing the unacceptability of offering such genetic tests outside of the traditional health care setting, without an established physician-patient relationship and without face-to-face medical supervision.
Recently, the German Ethics Council tabled recommendations on genetic diagnosis to the government asking for international rules for DCT testing and a duty to have face-to-face counselling before any of those tests. According to the survey, patients need qualified information on clinical significance, medical relevance and validity of such tests.
12.02.2016 The promise of the microbiome as the basis of new treatments has caught the attention of many. Now, UK biotherapeutics maker 4D pharma plc has padded its microbiome pipeline with the acquisition of Irish Tucana Health.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.